Ceftolozane/Tazobactam:

Objectives: The current study was aimed to investigate the antimicrobial susceptibility of ceftolozane/tazobactam (5th generation cephalosporin) against S. typhi. Design: Preclinical experimental study. Place and Duration of Study: The study was conducted at Baqai Medical University Karachi from April 2019 to July 2019. Patients and Methods: Total of 625 blood samples were collected from indoor and out-door patients using nonprobability sampling technique. The included samples were cultured in specific media and culture and sensitivity of antibiotics were analyzed through Kirby-Bauer disc diffusion technique on Mueller Hinton agar (Oxoid, England). Results: 200 samples were identified as positive S. typhi. Out of them 125 were recruited as MDR S. typhi. Analysis of demographic data showed 52% (n=66) female and 47% (n=59) male patients. The highest sensitivity was recorded against ceftolozane/tazobactam 94% and the highest resistance was recorded against chloramphenicol 92%, followed by ciprofloxacin 87% and ofloxacin 84%. Conclusion: Ceftolozane/Tazobactam could be an alternative choice in the treatment of MDR S. typhi infections.